| Features | |
| Active substance | Letrozole |
| Also known as | Letrozole |
| Blood pressure | May cause a decrease |
| Chemical name | Letrozole |
| Dosage (medical) | 2.5 mg once daily |
| Dosage (sports) | 1.25 mg to 2.5 mg every other day |
| Effects | Reduces estrogen levels, increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) |
| Formula | C17H11N5 |
| Half-life | Approximately 2 days |
| Hepatotoxicity | Low |
| Lab Test | Monitoring of blood estrogen levels and liver function tests |
| Main action | Inhibits the enzyme aromatase, which is involved in estrogen synthesis |
| Side effects | Hot flashes, joint pain, fatigue, risk of osteoporosis |
| Storage conditions | Store at room temperature away from moisture and heat |
| Substance class | Aromatase inhibitor |
| Trade name | Femara |
| Use in sports | Used to counteract the side effects of estrogen produced by aromatizing anabolic steroids |
| Water Retention | None |
| Active ingredient, mg | 2,5 |
| Release form | Tablets |
| 1 Pill, mg | 2,5 |
| Manufacturer | Driada Medical |
| Packing | Packaging (100 tablets) |
-
75.00€
Available Options
| Brand: | Moldavian Pharma |
|---|---|
| Product Code: | DRI-PA-5037-EU3 |
| Availability: | Available |
-494x235.png)